Apremilast

PRINCETON, N.J.--( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE: BMY) today announced results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), the pivotal Phase 3 trials evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both trials met their primary endpoint, with a significantly greater proportion of Sotyktu -treated patients achieving ACR20 response (at least a 20 percent improvement in signs and symptoms of disease) after 16 weeks of treatment compared with placebo. Additionally, the POETYK PsA-1 and POETYK PsA-2 trials met important secondary endpoints across PsA disease activity at Week 16. The overall safety profile of Sotyktu through 16 weeks of treatment in the POETYK PsA-1 and POETYK PsA-2 trials was consistent with the established safety profile of Sotyktu observed in a Phase 2 PsA clinical trial and Phase 3 moderate-to-severe plaque psoriasis clinical trials. "Psoriatic arthritis is a heterogenous disease that causes a range of different symptoms, including joint pain and swelling, as well as psoriatic skin lesions. Despite available therapies, rheumatologists continue to express a need for a safe and effective oral treatment," said Roland Chen , MD, senior vice president and head, Immunology, Cardiovascular and Neuroscience development, Bristol Myers Squibb. "These POETYK PsA-1 and POETYK PsA-2 findings demonstrate that oral Sotyktu has the potential to be the first TYK2 inhibitor for people living with psoriatic arthritis and reinforce the established efficacy and safety profile of Sotyktu . We are encouraged by the positive data across both Phase 3 trials and look forward to discussing the results with health authorities." Bristol Myers Squibb will work with key investigators to present detailed results at upcoming medical congresses. These topline results represent the first Phase 3 clinical trials for Sotyktu in a rheumatic condition. Sotyktu is approved in numerous countries around the world for the treatment of adults with moderate-to-severe plaque psoriasis. Bristol Myers Squibb thanks the patients, investigators and clinical trial sites who participated in these clinical trials. About the Sotyktu Phase 3 Psoriatic Arthritis Trial Program The Phase 3 Sotyktu psoriatic arthritis (PsA) program includes two Phase 3, multicenter, randomized, double-blind, placebo-controlled trials evaluating the efficacy and safety in adults 18 years of age and older with active PsA: POETYK PsA-1 (IM011-054; NCT04908202 ) and POETYK PsA-2 (IM011-055; NCT04908189 ). POETYK PsA-1 enrolled approximately 670 patients with active PsA who were not previously treated with a biologic disease-modifying antirheumatic drug (bDMARD naïve). POETYK PsA-2 enrolled approximately 730 patients with active PsA who were bDMARD naïve or had previously received TNFα inhibitor treatment. Both trials include a 52-week treatment period comprised of a placebo-controlled treatment period through Week 16, followed by a reallocation and continued active treatment period from Week 16 to Week 52. POETYK PsA-2 also included an apremilast safety reference arm. The primary endpoint of both trials was the proportion of participants achieving an ACR20 response at Week 16. Important secondary endpoints were also assessed at Week 16 across measures of PsA disease activity. Patients in both trials completing 52 weeks of treatment are potentially eligible to enroll in the open-label extension study. About Psoriatic Arthritis Psoriatic arthritis (PsA) is a chronic, immune-mediated, heterogenous disease with multiple musculoskeletal and skin manifestations, including inflammatory arthritis, enthesitis (inflammation where tendon or ligament attaches to the bone), dactylitis (swelling of finger and toe joints) and psoriatic skin and nail lesions. Up to 30 percent of patients with psoriasis will develop PsA. In addition to the loss of physical function, pain and fatigue caused by PsA, the disease can significantly impact the mental and emotional well-being of patients. Patients with PsA are also at increased risk of serious comorbidities, including cardiovascular disease, metabolic syndrome, depression and anxiety. About Sotyktu (deucravacitinib) Sotyktu (deucravacitinib) is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action, representing a new class of small molecules. It is the first selective TYK2 inhibitor in clinical studies across multiple immune-mediated diseases. Bristol Myers Squibb scientists designed Sotyktu to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-23, IL-12 and Type 1 interferons (IFN), key cytokines involved in the pathogenesis of multiple immune-mediated diseases. Sotyktu achieves a high degree of selectivity by binding to the regulatory domain of TYK2, resulting in allosteric inhibition of TYK2 and its downstream functions. Sotyktu selectively inhibits TYK2 at physiologically relevant concentrations. At therapeutic doses, Sotyktu does not inhibit JAK1, JAK2 or JAK3. Sotyktu is approved in numerous countries around the world for the treatment of adults with moderate-to-severe plaque psoriasis. Bristol Myers Squibb: Pursuing Bold Science in Immunology to Transform Patients’ Lives Bristol Myers Squibb is inspired by a single vision – transforming patients’ lives through science. For people living with immune-mediated diseases, the debilitating reality of enduring chronic symptoms and disease progression can make simple tasks and daily life a challenge. Driven by our deep understanding of the immune system that spans over 20 years of experience, we continue to pursue bold science as we work to deliver life-changing medicines that elevate new standards of care across rheumatology, dermatology and pulmonology. Our sequential immunotherapy research framework aims to address the root cause of disease by controlling inflammation, resetting the immune system and promoting immune homeostasis with the goal of achieving transformational efficacy. By continuously pushing the boundaries of scientific knowledge, we strive to bring forward tailored approaches, treatments and combinations that may lead to durable remissions, improved quality of life and functional cures. Our collaborations with patients, caregivers, healthcare providers and researchers inform our patient-centric approach as we aim to break efficacy ceilings and deliver what matters most – the promise of living a better life. SOTYKTU U.S. INDICATION SOTYKTU ® (deucravacitinib) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Limitations of Use: SOTYKTU is not recommended for use in combination with other potent immunosuppressants. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS SOTYKTU is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in SOTYKTU. WARNINGS AND PRECAUTIONS Hypersensitivity: Hypersensitivity reactions such as angioedema have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue SOTYKTU. Infections: SOTYKTU may increase the risk of infections. Serious infections have been reported in patients with psoriasis who received SOTYKTU. The most common serious infections reported with SOTYKTU included pneumonia and COVID-19. Avoid use of SOTYKTU in patients with an active or serious infection. Consider the risks and benefits of treatment prior to initiating SOTYKTU in patients: with chronic or recurrent infection who have been exposed to tuberculosis with a history of a serious or an opportunistic infection with underlying conditions that may predispose them to infection. Closely monitor patients for the development of signs and symptoms of infection during and after treatment. A patient who develops a new infection during treatment should undergo prompt and complete diagnostic testing, have appropriate antimicrobial therapy initiated and be closely monitored. Interrupt SOTYKTU if a patient develops a serious infection. Do not resume SOTYKTU until the infection resolves or is adequately treated. Viral Reactivation Herpes virus reactivation (e.g., herpes zoster, herpes simplex) was reported in clinical trials with SOTYKTU. Through Week 16, herpes simplex infections were reported in 17 patients (6.8 per 100 patient-years) treated with SOTYKTU, and 1 patient (0.8 per 100 patient-years) treated with placebo. Multidermatomal herpes zoster was reported in an immunocompetent patient. During PSO-1, PSO-2, and the open-label extension trial, the majority of patients who reported events of herpes zoster while receiving SOTYKTU were under 50 years of age. The impact of SOTYKTU on chronic viral hepatitis reactivation is unknown. Consider viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting and during therapy with SOTYKTU. If signs of reactivation occur, consult a hepatitis specialist. SOTYKTU is not recommended for use in patients with active hepatitis B or hepatitis C. Tuberculosis (TB): In clinical trials, of 4 patients with latent TB who were treated with SOTYKTU and received appropriate TB prophylaxis, no patients developed active TB (during the mean follow-up of 34 weeks). One patient, who did not have latent TB, developed active TB after receiving 54 weeks of SOTYKTU. Evaluate patients for latent and active TB infection prior to initiating treatment with SOTYKTU. Do not administer SOTYKTU to patients with active TB. Initiate treatment of latent TB prior to administering SOTYKTU. Consider anti-TB therapy prior to initiation of SOTYKTU in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during treatment. Malignancy including Lymphomas: Malignancies, including lymphomas, were observed in clinical trials with SOTYKTU. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with SOTYKTU, particularly in patients with a known malignancy (other than a successfully treated non-melanoma skin cancer) and patients who develop a malignancy when on treatment with SOTYKTU. Rhabdomyolysis and Elevated CPK: Treatment with SOTYKTU was associated with an increased incidence of asymptomatic creatine phosphokinase (CPK) elevation and rhabdomyolysis compared to placebo. Discontinue SOTYKTU if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. Instruct patients to promptly report unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever. Laboratory Abnormalities: Treatment with SOTYKTU was associated with increases in triglyceride levels. Periodically evaluate serum triglycerides according to clinical guidelines during treatment. SOTYKTU treatment was associated with an increase in the incidence of liver enzyme elevation compared to placebo. Evaluate liver enzymes at baseline and thereafter in patients with known or suspected liver disease according to routine management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt SOTYKTU until a diagnosis of liver injury is excluded. Immunizations: Prior to initiating therapy with SOTYKTU, consider completion of all age-appropriate immunizations according to current immunization guidelines including prophylactic herpes zoster vaccination. Avoid use of live vaccines in patients treated with SOTYKTU. The response to live or non-live vaccines has not been evaluated. Potential Risks Related to JAK Inhibition: It is not known whether tyrosine kinase 2 (TYK2) inhibition may be associated with the observed or potential adverse reactions of Janus Kinase (JAK) inhibition. In a large, randomized, postmarketing safety trial of a JAK inhibitor in rheumatoid arthritis (RA), patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism, and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. SOTYKTU is not approved for use in RA. ADVERSE REACTIONS Most common adverse reactions (≥1% of patients on SOTYKTU and more frequently than with placebo) include upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis and acne. SPECIFIC POPULATIONS Pregnancy: Available data from case reports on SOTYKTU use during pregnancy are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Report pregnancies to the Bristol Myers Squibb Company’s Adverse Event reporting line at 1-800-721-5072. Lactation: There are no data on the presence of SOTYKTU in human milk, the effects on the breastfed infant, or the effects on milk production. SOTYKTU is present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SOTYKTU and any potential adverse effects on the breastfed infant from SOTYKTU or from the underlying maternal condition. Hepatic Impairment: SOTYKTU is not recommended for use in patients with severe hepatic impairment. SOTYKTU is available in 6 mg tablets. Please see U.S. Full Prescribing Information , including Medication Guide , for SOTYKTU. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , X , YouTube , Facebook and Instagram . Cautionary Statement Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that future study results may not be consistent with the results to date, that Sotyktu (deucravacitinib) may not receive regulatory approval for the additional indication described in this release in the currently anticipated timeline or at all, any marketing approvals, if granted, may have significant limitations on their use, and, if approved, whether Sotyktu for such additional indication will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2023, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. corporatefinancial-news

胶质母细胞瘤（GBM）具有高度侵袭性，会从中心肿块迅速扩散，很难完全根除，是成人最常见的原发性恶性脑肿瘤。 据INC（ 国际神经外科医生集团）10年生存期胶质母细胞瘤患者的系统回顾研究，胶质母细胞瘤10年长期存活者的比例确定为0.76％，GBM复发率较高（在75-90％的患者中）在距原始病变边界2到3 cm之内，并且在治疗后5％的病例中发现多发性病变。 在Codon Publications2017年出版的一篇文章《Epidemiology and Outcome of Glioblastoma》中提到¹，在过去的三十年中，GBM 患者的生存率在人口统计数据中没有显着改善。为此，必须找到一种可靠的药物来提高GBM患者的存活概率。 在GBM的研究中，一些特定的分子和信号通路因其在肿瘤发展中的作用而成为研究的焦点。一项研究数据表明²在18例GBM 肿瘤中，CDK4和CDK6 的表达相对于匹配的正常脑组织升高（44%），证明了CDK4和CDK6在星形胶质细胞瘤发生中的功能重要性，尤其是在肿瘤进展的后期。 在这种市场需求和行业机遇下，美国生物制药公司BioTheryX利用其PRODEGY平台研发出BTX-9341。BTX-9341是一种细胞周期蛋白依赖性激酶4（CDK4）和细胞周期蛋白依赖性激酶6（CDK6）的研究性口服和双功能降解剂，在CDK4/6抑制剂初始和耐药临床前模型中均显示出显着的抗肿瘤活性。 BioTheryX成立于2007年，至今共筹集1.3亿美元融资。2020年获得MSD Partners领投的3500万美元D轮融资，紧接着在2021年获得由Farallon Capital Management领投的9200万美元E轮融资。 BioTheryX 融资历程 动脉网制图 01 攻克“不可成药”，实现3种分子降解方法 许多人类疾病是由异常蛋白质表达驱动的，但约85%的蛋白质被认为是“不可成药”的。基于蛋白酶体开发出的靶向蛋白质降解（TPD）技术，可通过重新利用内源性蛋白质处理系统来去除致病蛋白质，从而为那些难以攻克的疾病提供治疗的可能。 BioTheryX是一家处于临床阶段的生物制药公司，致力于通过蛋白质调节（包括TPD以及多激酶抑制）来恢复蛋白质稳态，以开发可延长并改善危及生命的疾病患者的生活质量的治疗方法。 BioTheryX的创始和科学团队的成员之前开发了IMiDs（免疫调节药物），这是美国FDA于1998年批准的第一个Cereblon（CRBN)调节剂，Cereblon是参与蛋白降解最广泛验证的E3连接酶。 自2001年Crews等首次提出PROTAC（Proteolysis Targeting Chimeras,蛋白降解靶向联合体）的概念以来，该技术不断发展与完善，越来越多的科研人员致力于通过PROTAC靶向降解目标蛋白³。 PROTAC是一种创新的靶向蛋白降解策略，通过小分子嵌合体同时招募目标蛋白（POI）和E3泛素连接酶，诱导目标蛋白的泛素化进而被蛋白酶体降解。其核心机制是利用细胞内的泛素-蛋白酶体系统（UPS）来诱导目标蛋白的降解。这个系统通过一系列的生化反应，将特定的蛋白质标记为“待降解”，然后将其分解成小肽和氨基酸，以便回收利用。 E3连接酶是泛素化过程中的最后一个酶，它直接将泛素分子转移到目标蛋白质上，从而标记这些蛋白质被降解。Cereblon就是这样一种E3连接酶，它参与了某些蛋白质的泛素化和随后的降解过程。 值得一提的是，Cereblon作为E3连接酶在PROTAC技术中被成功用于靶向多种蛋白质，适应症范围广，涵盖从癌症和免疫疾病，到神经退行性疾病相关蛋白（Tau），甚至到丙型肝炎病毒蛋白（NS3）。  蛋白质降解的自然过程 图源：BioTheryX官网 利用在Cereblon结合方面的专业知识，BioTheryX构建了这一种新的、强大的靶向蛋白质降解药物发现引擎——PRODEGY平台（Protein Degrader Technology），旨在设计和开发一流的双功能降解剂（TPD），以解决重大未满足的医疗需求。 据《Nature》，目前的TPD领域主要涵盖三种类型的分子：分子胶（Molecular Glues）、异双功能降解剂（heterobifunctional degraders）和选择性雌激素受体降解剂（SERD）。 同时，PRODEGY也实现了三种分子降解方法：分子胶，双功能降解剂（bifunctional degraders）和混合降解剂（hybrids degraders）。 分子胶是一类小分子化合物，它们能够诱导或稳定两种蛋白质之间的相互作用，包括目标蛋白和E3泛素连接酶，从而促进目标蛋白的泛素化和降解。通过PRODEGY平台，分子胶使 Cereblon 能够在没有结合口袋的情况下结合和降解一系列新底物——扩大目前15%“可成药”蛋白质的范围，并克服了传统基于抑制剂方法的许多局限性。 异双功能降解剂通常具有更复杂的结构，如PROTAC，具有“哑铃”结构，包括两个不同的配体和一个连接子，而双功能降解剂结构更简单，直接通过一个配体与E3连接酶和目标蛋白相互作用。通过PRODEGY设计双功能降解剂，可优化蛋白的定向，以实现高效的泛素化和降解。 双功能降解剂 图源：BioTheryX官网  混合降解剂既可作为分子胶，也可以作为双功能降解剂，在使用单个分子降解蛋白质和新底物方面具有更大的灵活性。使用PRODEG平台，可以使用同一分子降解新底物和具有结合口带的蛋白质。这些分子称为混合降解剂。 BioTheryX公司正在利用人体天然的蛋白质稳态机制，开发一种新方法来降解那些在自然条件下通常不会被分解的特定蛋白质。这种方法有潜力治疗多种由异常蛋白引起的疾病。基于这一原理，公司开发了其专有的PRODEGY平台，旨在通过创造一流的蛋白质降解剂，包括双功能降解剂和分子胶，来靶向癌症和炎症性疾病中的关键验证靶点。 02 达成4.77亿美元合作，最快管线已进入Ⅰ期临床 2023年4月，BioTheryX 与 Incyte（全球性生物制药公司）达成了一项研究合作和许可协议，以发现和开发针对多个历史上无法成药的新型肿瘤靶点的靶向蛋白质降解剂。 根据协议条款，BioTheryX 将利用其独特的 PRODEGY 平台来识别并初步开发用于多个“不可成药”的肿瘤靶点的分子胶降解剂。对于初始目标，BioTheryX 将获得 700 万美元的技术访问费，外加 Incyte 提供的高达 600万美元的额外潜在研发资金，用于支付与合作相关的费用。BioTheryX 还有资格获得高达3.47 亿美元的潜在未来监管和商业里程碑，以及初始目标全球净产品销售额的分级个位数特许权使用费。而Incyte 将全权负责 BioTheryX 的 PRODEGY平台发现的任何分子胶降解剂的进一步开发和商业化。 此外，BioThery司正利用其专有的PRODEGY平台推进一系列蛋白质降解剂的研发。在这一平台的支持下，公司进展最快的管线药物BTX-9341已经实现了1期临床试验的首例患者给药。 BioTheryX的管线项目  图源：BioTheryX官网 BTX-9341 是 CDK4/6 的同类首创口服降解剂，是一系列癌症的重要靶点，并在 HR+/HER2- 乳腺癌中得到临床验证。 BTX-10908是SOS1的同类首创口服降解剂，它在多个KRAS突变癌细胞系中显示出快速有效的SOS1降解作用，并在体内KRAS驱动的模型中抑制肿瘤生长。 PED4(磷酸二酯酶4)是经过高度验证的自身免疫和炎症性疾病靶点。在临床验证抑制关键炎性细胞因子（如 TNF-α、IFN-γ 和 IL-1β）方面显示出高达4,000倍的效力。 03 创始团队曾领导开发泊马度胺，分子胶赛道迎来MNC扎堆 如果说BioTheryX近几年的快速发展取得的研究成果构成了一张出色的蛋白质降解剂答卷，那么这份答卷无疑凝聚了背后团队的共同努力和智慧。 BioTheryX创始人Miles  Houslay教授和David  Stirling博士曾领导了第一代降解剂的发现和开发——免疫调节药物（IMiDs）——Revlimid（来那度胺）和 Pomalyst（泊马度胺）。 Miles Houslay目前担任伦敦国王学院的药理学创新教授，同时也是BioGryffe Consulting Ltd的首席执行官/董事总经理。BioGryffe Consulting Ltd是一家生物技术咨询公司，专注于将细胞信号研究转化为治疗和诊断应用，主要研究领域为细胞信号传导系统，尤其是环核苷酸信号网络的调控机制。Houslay教授已发表超过440篇研究论文，包括在《Science》、《Nature》等知名期刊上发表的文章。此外，他还曾担任亚洲、欧洲、日本、英国和美国多家公司的顾问或科学顾问委员会成员。 David Stirling曾担任BioTheryX的首席科学官和药物研发执行副总裁，同时他也是生物制药龙头企业Celgene（新基）的联合创始人。Stirling博士负责启动了Thalomid®（沙利度胺）的临床和研究计划，该计划促成了Celgene的第一个临床产品Thalomid®的成功上市。在Stirling博士的领导下，Celgene获得开发 Thalomid® 衍生物（Revlimid®、Pomalyst® 和 Otezla®阿普米斯特）的重磅特许经营权。 BioTheryX的首席执行官和董事会成员是Leah Fung 博士。Fung 博士创建了 BioTheryX 的分子胶筛选文库，用于新型新底物的发现，并指导了超过 25 项美国专利，涵盖了广泛的小分子蛋白质降解剂。 在此之前，Fung 博士曾担任 NovoMedix（专注于开发用于治疗癌症、纤维化和炎症性疾病的新型小分子多通路调节剂的生物技术公司 ）药物化学副总裁、Structural Genomix（领先的高通量结构生物学公司）药物化学副总监以及 Structural Bioinformatics （计算蛋白质组领域的全球领导者）药物化学助理总监。此外，她还是开创组合化学技术（一种快速合成和筛选大量化合物的方法，它允许科学家快速评估大量化合物的生物活性，从而识别出潜在的药物候选物）的领先科学家之一，40 多项已颁发美国专利和数百项国际专利的共同发明人。 2015年以前，靶向蛋白质降解市场资本参与热度极低。伴随着泊马度胺等分子胶药物的作用机制被完全阐明，人们对蛋白降解市场的关注度迅速提升。  蛋白降解赛道发展概况 图源：动脉网蛋壳研究院 目前，国内外已有多家公司以自主研究或商业合作方式布局蛋白降解。据动脉网蛋壳研究院，我国约20余公司参与布局，近半数现有蛋白降解公司在17-19年成立。2021年至2022年MNC在蛋白降解赛道达成的合作项目达14项，是2021年前达成项目数的总和。仅过去一年，合作项目披露金额超60亿美金，合作数量平均每月一项。药企投资合作的标的也从赛道中的几家代表性头部企业扩张到更多有特色专研于细分方向的初创企业。  MNC商业合作盘点 图源：动脉网蛋壳研究院 2022年 1月30日，工业和信息化部等 9 部门联合发布《“十四五”医药工业发展规划》，将包括 PROTAC 的靶向蛋白降解技术在内的前沿核心技术和药物列为重点发展对象。 据Data Bridge Market Research（全球市场研究和咨询公司），2021年靶向蛋白质降解市场规模为1.0331 亿美元，到 2029 年将飙升至 2.247 亿美元，预计在2022年至 2029年的预测期内复合年增长率为10.20%。 参考资料： 1.Tamimi, Juweid. Codon Publications 8, (2017） 2.Lam, Tomaso, et al. Brit J Neurosurg, 14(1), 28–32 (2000) 3.SAKAMOTO K M, KIM K B, KUMAGAI A, et al. Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation[J]. Proc Natl Acad Sci U S A,2001,98(15):8554-8559.doi:10.1073/pnas.141230798 如果您想对接文章中提到的项目，或您的项目想被动脉网报道，或者发布融资新闻，请与我们联系；也可加入动脉网行业社群，结交更多志同道合的好友。 近 期 推 荐 声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。 动脉网，未来医疗服务平台